Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation

Overview

About this study

This is a randomized, multicenter, open-label, active control study to assess the safety and efficacy of tegoprubart compared with tacrolimus in the preservation of allograft function after kidney transplantation. Approximately 120 de novo kidney transplant recipients will receive rATG (Thymoglobulin®) induction, corticosteroid maintenance, mycophenolate, and will be randomized 1:1 to receive either tegoprubart 20 mg/kg intravenously (IV) every 21 days after an initial loading period or twice daily oral tacrolimus.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

* Male or female ≥ 18 years of age
* Recipient of their first kidney transplant from a living or deceased donor
* Agree to comply with contraception requirements during and for at least 90 days after the last administration of study drug

Exclusion Criteria:

* Induction therapy, other than study assigned rATG, planned as part of initial immunosuppressive regimen
* Currently treated with any systemic immunosuppressive regimen, including immunologic biologic therapies
* Currently treated with corticosteroids other than topical or inhaled corticosteroids
* Will receive a kidney with an anticipated cold ischemia time of \> 30 hours
* Will receive a kidney from a donor that meets any of the following:

* 5a. Donation after Cardiac Death (DCD) criteria; Or
* 5b. Kidney Donor Profile Index (KDPI) of \> 85%; Or
* 5c. Is blood group (ABO) incompatible
* Medical conditions that require chronic use of systemic corticosteroids or other immunosuppressants
* History of a thromboembolic event, known hypercoagulable state, or condition requiring long term anticoagulation
* Positive T- or B-cell crossmatch that is due to HLA antibodies or presence of a DSA at Screening

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 5/21/2024. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Andrew Bentall, M.B., Ch.B., M.D.

Closed for enrollment

Contact information:

Julie Gecox Hanson CCRP

(507) 293-6592

Gecox.Julie@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20558964

Mayo Clinic Footer